We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · January 27, 2022

64Cu-DOTA-Trastuzumab and Response to Trastuzumab Emtansine

Journal of Nuclear Medicine

 

Additional Info

Journal of Nuclear Medicine
Use of 64Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine (T-DM1) for Metastatic Breast Cancer: A Pilot Study
J. Nucl. Med. 2021 Dec 02;[EPub Ahead of Print], JE Mortimer, JR Bading, PH Frankel, M Caroll, Y Yuan, J Park, L Tumyan, N Gidwaney, EK Poku, JE Shively, D Colcher

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading